Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

DELMED EXPECTS 1990 SALES OF DIALYSIS PRODUCTS TO FALL "SIGNIFICANTLY" below 1989 levels following the expected termination of Delmed's supply agreement with National Medical Care. The three-year exclusive supply agreement between the two firms expires in March 1990, and the companies have not been able to come to terms on prices and volume beyond that point, Delmed said Oct. 24. Delmed expects to continue supplying NMC after March 1990, but not at the minimum purchase levels stipulated under the current contract. NMC accounted for 87% of Delmed's 1988 revenues of $21.1 mil. NMC orders are down from last year, a Delmed spokesperson said. At the half, Delmed reported sales of $11.8 mil., up 13.7%, and a net loss of $2.6 mil. compared with a loss of $944,000 for the same period the year earlier. * The break with NMC throws a wrench into Delmed's plans for a merger with Fresenius USA. Delmed says that it "continues to explore the possibility of a combination," but on "substantially less favorable" terms than previously announced. In June, Delmed announced preliminary discussions for a merger with the U.S. subsidiary of West German firm Fresenius AG. At that point, the firms contemplated the issue of 123.5 mil. new shares of Delmed common for sale to Fresenius AG at 65 to 75 a share, as well as the purchase of additional Delmed shares by Fresenius. Valued at $80 mil., the transaction would have raised Fresenius' stake in Delmed from 45% to between 70% and 80%. Now, Delmed says that it is "not possible to provide the new terms of the combination since a proposal is presently being formulated by Fresenius AG. However, Delmed anticipates that the terms will call for Fresenius AG and Fresenius USA collectively to own at least 80% of the equity of Delmed, with the remainder continuing to be in the hands of the public." In addition, Delmed still expects some cash to be infused into the company, but less than the $10 mil. originally planned. * Another immediate ramification of the NMC termination is a Delmed management shakeup: Robert Ehrlich has stepped down as chairman, president and CEO, but will continue as a director and consultant. Leslie Shapiro resigned as chief operating officer and chief financial officer, Delmed said. Fresenius director Gerd Krick has become chairman of Delmed, and Fresenius USA President Ben Lipps has taken on the roles of Delmed president, chief executive and chief operating officer.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts